Blue­print Med­i­cines gets more ducks in a row be­fore CEO tran­si­tion; Paul Stof­fels has his work cut out for him at Gilead’s crum­bling part­ner

→ When Jeff Al­bers an­nounced he would no longer be CEO of Blue­print Med­i­cines, the lead­er­ship carousel at the Aykak­it mak­er had yet to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.